Please use this identifier to cite or link to this item: http://hdl.handle.net/2067/1577
Title: The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses
Authors: Sartorius, Rossella
Pisu, Paola
D'Apice, Luciana
Pizzella, Luciano
Romano, Chiara
Cortese, Giancarlo
Giorgini, Angela
Santoni, Angela
De Berardinis, Piergiuseppe
Velotti, Francesca Romana
Keywords: Vaccine;Cytotoxic T lymphocytes;Tumor immunology;Bladder cancer
Issue Date: 2008
Publisher: American Association of Immunologists
Source: Sartorius, R. et al. 2008. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. "Journal of Immunology" 180 (6): 3719-3728
Abstract: 
Delivery of tumor-associated antigen (TAA)-derived peptides in a high immunogenic form represents one of the key issues for effective peptide-based cancer vaccine development. Here, we report the ability of non-pathogenic filamentous bacteriophage fd virions to deliver HLA-A2-restricted MAGE-A10254-262- or MAGE-A3271-279-derived peptides and elicit potent specific CTL responses in vitro and in vivo. Interestingly, human anti-MAGE-A3271-279-specific CTLs were able to kill human MAGE-A3+ tumor cells, even if these cells naturally express a low amount of MAGE-A3271-279 peptide-HLA epitope surface complexes and are usually not recognized by CTLs generated by conventional stimulation procedures. MAGE-A3271-279-specific/CD8+ CTL clones were isolated from in vitro cultures and their high avidity for antigen recognition was assessed. Moreover, in vivo tumor protection assay showed that vaccination of humanized HHD (HLA-A2.1+/H2-Db+) transgenic mice with phage particles expressing MAGE-A3271-279-derived peptides hampered tumor growth. Overall, these data indicate that engineered filamentous bacteriophage virions increase substantially the immunogenicity of delivered TAA-derived peptides, thus representing a novel powerful system for the development of effective peptide-based cancer vaccines.
Description: 
L'articolo è disponibile sul sito dell'editore http://www.jimmunol.org
URI: http://hdl.handle.net/2067/1577
ISSN: 0022-1767
Appears in Collections:DECOS - Archivio della produzione scientifica

Files in This Item:
File Description SizeFormat
JImmunology1577.pdf111.56 kBAdobe PDFView/Open
Show full item record

Page view(s)

2
Last Week
0
Last month
0
checked on Dec 3, 2020

Download(s)

2
checked on Dec 3, 2020

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.